Geoffroy Pineau-Valencienne has extensive experience in venture capital, private equity, M&A, and capital markets transactions. He represents a large number of private and public companies at every stage of development, from entrepreneurial start-ups to global corporations, particularly in the life sciences and technology fields, as well as financial and industrial investors.
He also represents, on a regular basis, tech and biopharmaceutical companies in transactional matters in relation to joint ventures and strategic partnerings, product development, distribution, and licensing agreements.
Geoffroy's recent experience includes representation of technology and life sciences companies such as Amoéba, Amolyt Pharma, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Orega Biotech, Orphélia Pharma, Talend, Trace One, and Urban Canopée. His recent investor-side representations include: Alven, Andera, Balderton, BioMed, Bpifrance, CEA Investissement, CITA, Elaia, Fa-Dièse, Havenrock, HI Inov, Hil-Invest, Idinvest, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Supernova, Ventech, Wellington, and Western Digital.
Illustrative examples of the transactions in which Geoffroy acted as lead lawyer include IPOs and follow-on offerings (Amoéba, Genticel, and Enertime on the main or Growth market of Euronext Paris and Cellectis and Talend on Nasdaq), private and public M&A transactions (the acquisition of Pipplet by ETS Global; the sales of Alizé Pharma to Millendo, Mathym to Baikowski, Endocontrol to Canady Life Sciences, and SoCloz to Savoye; and the reverse merger of Genticel to Genkyotex), and venture capital financings, either on issuer- or investor-side (in connection with the financing rounds of Amolyt Pharma, Alédia, Inotrem, Mutabilis, Lendix, UpMem, Urban Canopée, UroMems, and TriCares).
- New York University (LL.M. in Business Law 2002); Université de Paris II-Panthéon Assas (DESS in Business Law and Taxation 1998; Maîtrise with high honors 1997)
- Paris Bar
Private Equity: Venture Capital: Chambers Europe (Band 1) and The Legal 500 EMEA (Tier 1) — "very high quality team, perfectly mastering the legal and business issues of transactions" (2023)
Venture Capital: team acknowledged as leader in France since 2000 — Option Droit & Affaires, Décideurs, and Private Equity Magazine
M&A: team ranked 4 stars for M&A deals greater than €200 million in France — Option Droit & Affaires (2023, 2022)
- English, French